Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models.

Broutin S, Ameur N, Lacroix L, Robert T, Petit B, Oumata N, Talbot M, Caillou B, Schlumberger M, Dupuy C, Bidart JM.

Clin Cancer Res. 2011 Apr 1;17(7):2044-54. doi: 10.1158/1078-0432.CCR-10-2041. Epub 2011 Feb 15.

2.

Sunitinib: from rational design to clinical efficacy.

Chow LQ, Eckhardt SG.

J Clin Oncol. 2007 Mar 1;25(7):884-96. Review.

PMID:
17327610
3.

Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.

Santarpia L, Ye L, Gagel RF.

J Intern Med. 2009 Jul;266(1):99-113. doi: 10.1111/j.1365-2796.2009.02112.x. Review.

4.

Medullary thyroid cancer: therapeutic targets and molecular markers.

Ball DW.

Curr Opin Oncol. 2007 Jan;19(1):18-23. Review.

PMID:
17133107
5.

Targeting RET receptor tyrosine kinase activation in cancer.

Phay JE, Shah MH.

Clin Cancer Res. 2010 Dec 15;16(24):5936-41. doi: 10.1158/1078-0432.CCR-09-0786. Epub 2010 Oct 7. Review.

6.

Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers.

Santarpia L, Bottai G.

Curr Pharm Des. 2013;19(5):864-82. Review.

PMID:
22973956
7.

Sunitinib for the treatment of thyroid cancer.

Gómez-Sáez JM.

Expert Opin Investig Drugs. 2016 Nov;25(11):1345-1352. doi: 10.1080/13543784.2016.1242577. Epub 2016 Oct 6. Review.

PMID:
27677828
8.

Gene therapeutic approaches for medullary thyroid carcinoma treatment.

Drosten M, Pützer BM.

J Mol Med (Berl). 2003 Jul;81(7):411-9. Epub 2003 Jun 14. Review.

PMID:
12811413
9.

Thyroid C-Cell Biology and Oncogenic Transformation.

Cote GJ, Grubbs EG, Hofmann MC.

Recent Results Cancer Res. 2015;204:1-39. doi: 10.1007/978-3-319-22542-5_1. Review.

10.

Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.

Grüllich C.

Recent Results Cancer Res. 2014;201:207-14. doi: 10.1007/978-3-642-54490-3_12. Review.

PMID:
24756794
11.

Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy.

Vitale G, Dicitore A, Messina E, Sciammarella C, Faggiano A, Colao A.

Recent Pat Anticancer Drug Discov. 2016;11(3):275-82. Review.

PMID:
27306881
12.

Sunitinib: the antiangiogenic effects and beyond.

Hao Z, Sadek I.

Onco Targets Ther. 2016 Sep 8;9:5495-505. doi: 10.2147/OTT.S112242. eCollection 2016. Review.

Supplemental Content

Support Center